%0 Clinical Trial
%T Plasma heat shock protein 90-alpha have an advantage in diagnosis of colorectal cancer at early stage.
%A Kasanga M
%A Liu L
%A Xue L
%A Song X
%J Biomark Med
%V 12
%N 8
%D 08 2018
%M 29939072
%F 2.498
%R 10.2217/bmm-2018-0155
%X We investigated HSP90α as screening biomarker for early colorectal cancer (CRC).<BR>Seventy-seven CRC patients and 78 healthy controls were enrolled. Plasma HSP90α was significantly higher in CRC patients than in healthy controls (p < 0.05). levels were higher in late (stages III and IV) CRC than in early (stages I and II) CRC (p = 0.022). HSP90α conferred an advantage in the diagnosis of early CRC. Combination of HSP90α and carcinoembryonic antigen improved the diagnostic sensitivity (84.4%) and specificity (89.5%) for CRC (area under the curve: 0.968); for early CRC, the sensitivity was 82.5% and specificity was 89.5% (area under the curve: 0.955).<BR>HSP90 is a potential biomarker for the diagnosis of early CRC.